

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

**(I) RESIGNATION OF NON-EXECUTIVE DIRECTOR AND DEPUTY
CHAIRMAN OF THE BOARD;**
**(II) APPOINTMENT OF EXECUTIVE DIRECTOR AND MANAGING
DIRECTOR;**
AND (III) CHANGE OF JOINT COMPANY SECRETARY

**RESIGNATION OF NON-EXECUTIVE DIRECTOR AND DEPUTY CHAIRMAN OF THE
BOARD**

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. WANG Xiaochun (“**Mr. WANG**”) has resigned as the non-executive Director and deputy chairman of the Board with effect from 25 March 2022 due to personal health reason. Mr. WANG has vacated from the office as a member of each of the nomination committee (the “**Nomination Committee**”) and the strategic committee (the “**Strategic Committee**”) of the Company upon his resignation as a non-executive Director.

Mr. WANG has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. WANG for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF EXECUTIVE DIRECTOR AND MANAGING DIRECTOR

The Board is pleased to announce that Mr. CHENG Xueren (“**Mr. CHENG**”), the president of the Company, has been appointed as an executive Director and managing director of the Company, with effect from 25 March 2022. He will continue to be responsible for the implementation of the important policies and development strategies approved by the Board and has direct management responsibility for the daily operations of the Group. Mr. CHENG has also been appointed as a member of each of the Nomination Committee and Strategic Committee. The biographical details of Mr. CHENG are set out below:

Mr. CHENG, aged 58. Mr. CHENG was graduated from Anhui Institute of Traditional Chinese Medicine (currently known as Anhui University of Traditional Chinese Medicine) with a bachelor degree in Traditional Chinese Medicine in 1985, and obtained a master degree from Guangzhou University of Chinese Medicine in Basic Theory of Integrated Chinese and Western Medicine in 1992. Mr. CHENG has the professional qualifications of chief pharmacist and attending physician. Mr. CHENG was a physician of Anhui Chuzhou People’s Hospital from July 1985 to August 1989; a physician of Guangdong Second Hospital of Traditional Chinese Medicine from July 1992 to March 1993; a deputy manager of production, the deputy manager of sales and general manager of Guangdong Yifang Pharmaceutical Co., Ltd. (“**Guangdong Yifang**”) successively from March 1993 to November 2017, during which, he was the vice director of Guangdong Institute of Traditional Chinese Medicine from March 1993 to May 2015. Mr. CHENG was a vice president of the Company from December 2018 to September 2021, and the chairman, the secretary of the Party Committee and the general manager of Guangdong Yifang. He has been the president of the Company since September 2021 and holds directorships in a number of subsidiaries of the Company.

Save as disclosed above, Mr. CHENG (i) does not hold any other position within the Group; (ii) has not held directorships in any other listed companies in the past three years; (iii) has not held any other major appointment and professional qualifications; and (iv) does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

Mr. CHENG will enter into an employment agreement with the Company in relation to his appointment as the executive Director and managing director with effect from 25 March 2022, which shall automatically be effective hereafter. He shall hold office only until the next general meeting of the Company and shall then be eligible for re-election. Thereafter, Mr. CHENG is subject to retirement by rotation and re-election in accordance with the articles of association of the Company. The aggregate remuneration of Mr. CHENG as the executive Director and managing director is RMB2,450,000 per annum, which is determined by the remuneration and evaluation committee of the Company in accordance with reference to his duties, market rate, his time, effort, expertise and responsibilities to be exercised on the Group’s affairs and with the Company’s remuneration policy.

As at the date of this announcement, Mr. CHENG does not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. CHENG that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to Mr. CHENG that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome to Mr. CHENG on his appointment as the executive Director and managing director.

CHANGE OF JOINT COMPANY SECRETARY

The Board hereby announces that Ms. LEUNG Suet Lun (“**Ms. LEUNG**”) has resigned as one of the joint company secretaries of the Company due to work re-allocation, with effect from 25 March 2022.

Ms. LEUNG has confirmed that she has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange in relation to her resignation.

The Board further announces that Ms. NG Sau Mei (“**Ms. NG**”) has been appointed as the joint company secretary of the Company with effect from 25 March 2022. Mr. ZHAO Dongji will continue to serve as the other joint company secretary of the Company.

The biographical details of Ms. NG are set out below:

Ms. NG currently serves as the director and head of the listing services department of TMF Hong Kong Limited and is responsible for provision of corporate secretarial and compliance services to listed company clients. Ms. NG currently serves as company secretary or joint company secretary for numerous listed companies. Ms. NG has over 20 years of experience in the professional company secretarial field, and she is a Chartered Secretary, a Chartered Governance Professional and a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom.

The Board would like to take this opportunity to express its sincere gratitude to Ms. LEUNG for her valuable contribution to the Company during her tenure of office, and welcome Ms. NG to her new appointment.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
WU Xian
Chairman

Hong Kong, 25 March 2022

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. CHENG Xueren, and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.